A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis.

MLA

Lelegren, Matthew J., et al. “A Review of Phase III Clinical Trials of US FDA-Approved Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis.” Immunotherapy, vol. 14, no. 8, June 2022, pp. 655–62. EBSCOhost, https://doi.org/10.2217/imt-2021-0310.

APA

Lelegren, M. J., Son, S. Y., Han, J. K., & Lam, K. K. (2022). A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis. Immunotherapy, 14(8), 655–662. https://doi.org/10.2217/imt-2021-0310

Chicago

Lelegren, Matthew J, Sam Y Son, Joseph K Han, and Kent K Lam. 2022. “A Review of Phase III Clinical Trials of US FDA-Approved Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis.” Immunotherapy 14 (8): 655–62. doi:10.2217/imt-2021-0310.